QuidelOrtho (NASDAQ:QDEL) versus Oruka Therapeutics (NASDAQ:ORKA) Head to Head Survey

Oruka Therapeutics (NASDAQ:ORKA) and QuidelOrtho (NASDAQ:QDEL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Insider & Institutional Ownership

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are held by institutional investors. 22.7% of Oruka Therapeutics shares are held by insiders. Comparatively, 1.0% of QuidelOrtho shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Oruka Therapeutics has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, QuidelOrtho has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500.

Earnings and Valuation

This table compares Oruka Therapeutics and QuidelOrtho”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$5.34 million	($6.26)	-3.31
QuidelOrtho	$3.00 billion	0.90	-$10.10 million	($27.90)	-1.44

Oruka Therapeutics has higher earnings, but lower revenue than QuidelOrtho. Oruka Therapeutics is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Oruka Therapeutics and QuidelOrtho, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	7	1	3.13
QuidelOrtho	1	3	3	0	2.29

Oruka Therapeutics presently has a consensus target price of $43.17, indicating a potential upside of 108.03%. QuidelOrtho has a consensus target price of $58.83, indicating a potential upside of 46.57%. Given Oruka Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Oruka Therapeutics is more favorable than QuidelOrtho.

Profitability

This table compares Oruka Therapeutics and QuidelOrtho’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-24.96%	-21.22%
QuidelOrtho	-66.25%	4.24%	2.17%

Summary

Oruka Therapeutics beats QuidelOrtho on 9 of the 14 factors compared between the two stocks.

About Oruka Therapeutics

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.